VA and DoD ordered to offer experimental nerve-block PTSD treatment to veterans
H.R. 1947 — TREAT PTSD Act · Filed by Scott Perry (R-PA) · 13 cosponsors · Introduced Mar 6, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Department of Veterans Affairs and Department of Defense to offer stellate ganglion block (SGB)—a nerve-blocking injection used experimentally to treat PTSD symptoms—to eligible veterans and active-duty service members who have been diagnosed with PTSD and consent to the procedure. The VA and DoD must also update their joint clinical practice guidelines within 180 days to reflect SGB as a therapy option and inform Congress of the update.
Why we flagged it
The bill's sole operative mechanism is to expand access to a specific medical treatment (stellate ganglion block) for a defined population (veterans and service members with PTSD) through existing federal healthcare systems. It is a straightforward healthcare access measure.
What the text implies
- SGB is an emerging/experimental treatment for PTSD with mixed evidence; widespread VA/DoD adoption may increase demand for a procedure that remains under clinical investigation, potentially affecting resource allocation within military healthcare.
- The 180-day guideline update requirement creates a tight timeline for VA/DoD to integrate SGB into clinical practice; implementation delays or incomplete guidance could create inconsistent access across facilities.
The full analysis lists 3 implications of this text.
Who stands to gain
medical device/pharmaceutical companies manufacturing or supplying stellate ganglion block materials; healthcare providers and anesthesiologists trained to administer SGB